adalimumab

Key facts

INN

adalimumab

Brand

HUMIRA

Formulation

VIAL

Related patents

patent

US 12246064

Method of treating Crohn's disease by administering a triple combination therapy

Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

patent

US 11229702

High concentration formulations of adalimumab

Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

patent

US 10799585

Stable aqueous formulations of adalimumab

Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

patent

US 10786566

Stable aqueous formulations of adalimumab

Expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

patent

US 10780163

Stable aqueous formulations of adalimumab

Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

patent

US 10772959

Stable aqueous formulations of adalimumab

Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

patent

US 10772960

Stable aqueous formulations of adalimumab

Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

patent

US 10722579

Stable aqueous formulations of adalimumab

Expires Mon Jul 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

Related news

NewsImmunologyMar 31, 2026

FDA Approves First Interchangeable Humira Biosimilar: Key Details

The FDA has approved the first interchangeable biosimilar to Humira, a significant milestone for patients with autoimmune conditions seeking affordable treatment alternatives.

Dr. Sarah Mitchell

Frequently asked questions

What is adalimumab?

adalimumab (HUMIRA), is a pharmaceutical active ingredient, with approved status in the US.

What is the brand name for adalimumab?

HUMIRA is a marketed brand name for adalimumab. Check FDA Drugs@FDA for the current US label holder.